Clinical Trial Update: Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial of Vitespen (HSPPC-96, Oncophage) for immune response in resectable renal cell carcinoma at intermediate risk of recurrence; study terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Vitespen (HSPPC-96)

Snippet

Sponsor: Agenus Inc. | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2021-06-03